Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART: SBRT With or Without Darolutamide for Oligorecurrent Prostate Cancer
2019-004952-13Phase 2Active
- Sponsor
- Ghent University Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Metastasis-free survival. Started Aug 2020; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-004952-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004952-13.